搜索结果21-30 的 26153 / Adenocarcinoma

  1. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

    The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with ...

  2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with ...

  5. 神经科 - 临床试验 - 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma ...

  7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) in Patients with Metastatic Pancreatic Adenocarcinoma.

  8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Patients with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment. Exclusion ...

  9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Patients with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment. Exclusion ...

  10. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...